Definiens launches Tissue Studio 2.0 image analysis software for digital pathology

Definiens today announced the introduction of Definiens Tissue Studio™ 2.0, the latest version of the company's leading image analysis software for digital pathology.

Along with improved processing speed, the second iteration of Definiens Tissue Studio now includes a full range of functionality for the analysis of immunofluorescence tissue stains. With its "learn-by-example" format, users train the software to identify representative regions of interest, and configure the software to automatically identify cells and sub-cellular objects. Beside the analysis of whole virtual slides, Definiens Tissue Studio 2.0 also provides full support to process tissue micro arrays.  Pathologists do not need prior computer programming, and can develop customized image analysis solutions in as little as 20 minutes.

"The fantastic reception to Definiens Tissue Studio over the last year has demonstrated the growing need among pathologists for accurate biomarker detection and quantification tools," said Martin Baatz, Ph.D. Vice President of Marketing at Definiens. "With Definiens Tissue Studio 2.0, we are providing an increased level of accuracy and speed while preserving the accessible interface and workflow that has been embraced by our customers."  

Definiens Tissue Studio 2.0 is able to quantify localized biomarker expression as well as more than 50 morphological features. The rapid and accurate results provided by the software reveal underlying biological insights required for successful oncology translational research; supporting retrospective studies, diagnostics development, and early decision support in Phase I and Phase II clinical trials.

Definiens will introduce Definiens Tissue Studio 2.0 during an interactive webinar on Wednesday, August 4 at 11:00am ET. Details and registration are available at www.tissuestudio.com.

Source:

Definiens

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New nanoparticle platform delivers drug pairs to specific cancer types